CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Zoetis presents pipeline with major market approvals expected annually for next several years

By Public Technologies
  • Zoetis expects major market approvals every year for the next several years, according to its investor presentation.
  • Long-acting Cytopoint is expected in 2026; renal monoclonal antibody therapy is targeted for 2027.
  • Oncology monoclonal antibody therapies are expected in 2028-2029; obesity and anxiety treatments are targeted for 2030 onward.
  • A focused strategy aims to return Librela to growth in the osteoarthritis pain market.
  • The global animal health market is forecast to reach $85 billion-$95 billion by 2035, from about $50 billion in 2024.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.